SEARCH

SEARCH BY CITATION

References

  • 1
    Belt, J.A., Marina, N.M., Phelps, D.A., Crawford, C.R. (1993) Nucleoside transport in normal and neoplastic cells. Advances in Enzyme Regulation, 33, 235 252.
  • 2
    Boletti, H., Coe, J.R., Baldwin, S.A., Cass, C.E. (1997) Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology, 36, 1167 1179.
  • 3
    Burris III, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., Nelson, R., Dorr, A., Stephens, C.D., Von Hoff, D.D. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15, 2403 2413.
  • 4
    Callet-Bauchu, E., Rimokh, R., Tigaud, I., Pages, J., Gazzo, S., Bastion, Y., Sebban, C., Magaud, J.P., Coiffier, B. (1996) dic(4;17) (p11;p11): a new recurrent chromosomal abnormality in chronic B-lymphoid disorders. Genes, Chromosomes and Cancer, 17, 185 190.
  • 5
    Cheson, B.D. (1992) New antimetabolites in the treatment of human malignancies. Seminars in Oncology, 19, 695 706.
  • 6
    Crawford, C.R., Patel, D.H., Naeve, C., Belt, J.A. (1998) Cloning of the Human equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter by functional expression in a transport-deficient line. Journal of Biological Chemistry, 273, 5288 5293.
  • 7
    Dumontet, C., Duran, G.E., Steger, K.A., Murphy, G., Sussman, H., Sikic, B.I. (1996) Differential expression of tubulin isotypes during the cell cycle. Cell Motility and the Cytoskeleton, 35, 49 58.
  • 8
    Flasshove, M., Strumberg, D., Ayscue, L., Mitchell, B.S., Tirier, C., Heit, W., Seeber, S., Schutte, J. (1994) Structural analysis of the deoxycyticine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia, 8, 780 785.
  • 9
    Fox, M., Boyle, J.M., Kinsella, A.R. (1991) Nucleoside salvage and resistance to antimetabolite anticancer agents. British Journal of Cancer, 64, 428 436.
  • 10
    Gandhi, V., Danhauser, L., Plunkett, W. (1987) Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography. Journal of Chromatography, 413, 293 299.
  • 11
    Gandhi, V., Estey, E., Keating, M.J., Plunkett, W. (1996) Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia. Blood, 87, 156 164.
  • 12
    Gandhi, V., Huang, P., Chapman, A.J., Chen, F., Plunkett, W. (1997) Incorporation of fludarabine and 1-β-D-arabinofuranosylcytosine 5′-triphosphates by DNA polymerase alpha: affinity, interaction and consequences. Clinical Cancer Research, 3, 1347 1355.
  • 13
    Griffig, J., Koob, R., Blakley, R.L. (1989) Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Research, 49, 6923 6928.
  • 14
    Griffiths, M., Beaumont, N., Yao, S.Y.M., Sundaram, M., Boumah, C.E., Davies, A., Kwong, F.Y.P., Coe, I., Cass, C.E., Young, J.D., Baldwin, S.A. (1997 a) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nature Medicine, 3, 89 93.
  • 15
    Griffiths, M., Yao, S.Y.M., Abidi, F., Phillips, S.E.V., Cass, C.E., Young, J.D., Baldwin, S.A. (1997 b) Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochemical Journal, 328, 749 743.
  • 16
    Grunewald, R., Kantarjian, H., Du, M., Faucher, K., Tarasoff, P., Plunkett, W. (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. Journal of Clinical Oncology, 10, 406 413.
  • 17
    Hopkinson, D.A., Cook, P.J.L., Harris, H. (1969) Further data on the adenosine deaminase polymorphism and report of a new phenotype. Annals of Human Genetics, 32, 361 365.
  • 18
    ISCN (1995) An International System for Human Cytogenetic Nomenclature. Karger, Basel.
  • 19
    Iwasaki, H., Huang, P., Keating, M.J., Plunkett, W. (1997) Differential incorporation of Ara-C, gemcitabine and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood, 90, 270 278.
  • 20
    Jeannesson, P., Trentesaux, C., Gerard, B., Jardillier, J.C., Ross, K.L., Tokes, Z.A. (1990) Induction of erythroid differentiation in human leukemic K-562 cells by membrane-directed action of adriamycin covalently bound to microspheres. Cancer Research, 50, 1231 1236.
  • 21
    Juliusson, G. & Liliemark, J. (1996) Long-term survival following cladribine therapy in previously treated patients with chronic lymphocytic leukemia. Annals of Oncology, 7, 373 379.
  • 22
    Kawasaki, H., Carrera, C.J., Piro, L.D., Saven, A., Kipps, T.J., Carson, D.A. (1993) Relationship of deoxycytidine kinase and cytoplasmid 5′ nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood, 81, 597 601.
  • 23
    Keating, M.J., O'Brien, S., Kantarjian, H., Plunkett, W., Estey, E., Koller, C., Beran, M., Freireich, E.J. (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood, 11, 2878 2884.
  • 24
    Kroep, J.R., Van Moorsel, C.J., Veerman, G., Voorn, D.A., Schultz, R.M., Worzalla, J.F., Tanzer, L.R., Merriman, R.L., Pinedo, H.M., Peters, G.J. (1998) Role of deoxycytidine kinase, thymidine kinase 2, and deoxycytidine deaminase in the antitumour activity of gemcitabine. Advances in Experimental Medicine and Biology, 431, 657 660.
  • 25
    Lepoivre, M., Chenais, B., Yapo, A., Lemaire, G., Thelander, L., Tenu, J.P. (1990) Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. Journal of Biological Chemistry, 265, 14143 14149.
  • 26
    Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J. (1951) Protein measurement with Folin phenol reagent. Journal of Biological Chemistry, 193, 265 275.
  • 27
    Mackey, J.R., Baldwin, S.A., Young, J.D., Cass, C.E. (1998) Nucleoside transport and its significance for anticancer drug resistance. Drug Resistance Updates, 1, 310 324.
  • 28
    Plunkett, W., Hug, V., Keating, M.J., Chubb, S. (1980) Quantification of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Research, 40, 588 591.
  • 29
    Richel, D.J., Colly, L.P., Arkesteijn, G.J.A., Arentsen-Honders, M.W., Kerster, M.G.D., Ter Riet, P.M., Willemze, R. (1990) Substrate-specific deoxycytidine kinase deficiency in 1-β-D-arabinofuranosylcytosine-resistant leukemic cells. Cancer Research, 50, 6515 6519.
  • 30
    Rodriguez, C.O., Legha, J.K., Estey, E., Keating, M.J., Gandhi, V. (1997) Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clinical Cancer Research, 3, 2107 2113.
  • 31
    Ruiz van Haperen, V.W., Veerman, G., Braakhuis, B.J., Vermoken, J.B., Boven, E., Leyva, A., Peters, G.J. (1993) Deoxycytidine kinase and deoxycytidine deaminase activities in human tumor xenografts. European Journal of Cancer, 29A, 2132 2137.
  • 32
    Ruiz van Haperen, V.W.T., Veeman, G., Eriksson, S., Boven, E., Stegmann, A.P.A., Hermsen, M., Vermorken, J.B., Pinedo, H.M., Peters, G.J. (1994) Development and characterization of a 2,2-difluorodeoxycytidine-resistant variant of the human ovarian cancer cell line A2780. Cancer Research, 54, 4138 4143.
  • 33
    Santoro, A., Devizzi, L., Bonfante, V., Viviani, S., Soto Parra, H., Nowrousian, M., Seeber, S., Hiddemann, W., Oliva, C., Pacini, M., Buksmaui, S., Bonadonna, G., Diehl, V. (1997) Phase II study with gemcitabine in pretreated patients with Hodgkin's disease and non-Hodgkin's lymphoma: results of a multicenter study. American Society of Clinical Oncology, Abstract 71.
  • 34
    Sherman, P.A. & Fyfe, J.A. (1989) Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Analytical Biochemistry, 180, 222 226.
  • 35
    Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G., Cheson, B.D. (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C protocol mechanism of the National Cancer Institute: five-year follow-up report. Journal of Clinical Oncology, 15, 458 465.
  • 36
    Stegmann, A.P.A., Honders, M.W., Kester, M.G.D., Landegent, J.E., Willemze, R. (1993) Role of deoxycytidine kinase in an in vitro model for ara-C and DAC resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-arabinofuranosylcytosine and 5-aza-2-deoxycytidine. Leukemia, 7, 1005 1011.
  • 37
    Twentyman, P.R., Fox, N.E., Rees, J.K. (1989) Chemosensitivity testing of fresh leukaemic cells using the MTT colourimetric assay. British Journal of Haematology, 71, 19 24.
  • 38
    Ujhazy, P., Berleth, E.S., Pietkiewicz, J.M., Kitano, H., Skaar, J.R., Ehrke, M.J., Mihich, E. (1996) Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance. International Journal of Cancer, 68, 493 500.
  • 39
    Van Laarhoven, J.P.R.M., Spierenburg, G.T., De Bruyn, C.H.M.M. (1980) Enzymes of purine nucleotide metabolism in human lymphocytes. Journal of Immunological Methods, 39, 47 58.
  • 40
    Warzocha, K., Fabianowska-Majewska, K., Blonski, J., Krykowski, E., Robak, T. (1997) 2-Chloro-deoxyadenosine inhibits activity of adenosine deaminase and S-adenosylhomocysteine hydrolase in patients with chronic lymphocytic leukemia. European Journal of Cancer, 33, 170 173.